Clinicopathological spectrum of BCR-ABL-Negative myeloproliferative neoplasms with correlation with janus-associated kinase 2 mutation

Roopa Dixith; A Sara; Navatha Vangala; Shantveer G Uppin; Megha S Uppin; AMVR Narendra; Tara Roshni Paul

doi:10.4103/ijmpo.ijmpo_192_17

Indian Journal of Medical and Paediatric Oncology, Table of Contents

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2019; 40(01): 35-40
DOI: 10.4103/ijmpo.ijmpo_192_17

Original Article

Clinicopathological spectrum of BCR-ABL-Negative myeloproliferative neoplasms with correlation with janus-associated kinase 2 mutation

Authors

Roopa Dixith

Department of Pathology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
A Sara

Department of Pathology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
Navatha Vangala

Department of Pathology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
Shantveer G Uppin

Department of Pathology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
Megha S Uppin

Department of Pathology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
AMVR Narendra

Department of Hematology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
Tara Roshni Paul

Department of Pathology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India

Abstract

Background: Non chronic myelogenous leukemia (non-CML)/BCR-ABL-negative myeloproliferative neoplasms (MPNs) include essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF) (apart from chronic neutrophilic leukemia and chronic eosinophilic leukemia, which are rare). They are uncommon clonal disorders of adults, with an incidence ranging from 0.5 to 3/100,000 persons, BCR-ABL negative, and characterized by the activation of Janus-associated kinase 2 (JAK2). Very few studies have been reported from India. Aims and Objectives: The aims and objectives of this study were to analyze the clinicopathological spectrum and to determine the frequency of JAK2 mutation in patients of non-CML/BCR-ABL negative MPNs. Materials and Methods: Clinical and morphological features and frequency of JAK2 mutation in patients with PV, ET, and PMF were studied at a tertiary care hospital. The material was retrieved from the hematopathology records and reviewed. Results: JAK2V617F mutation was found in 10 of 14 cases (71%) of MPNs, 100% in PV, 50% in ET, and 71% of idiopathic myelofibrosis. The presence of JAK2V617F mutation was associated with a higher hemoglobin level (P < 0.05), a higher TLC (P < 0.05), and higher age (P < 0.05). Results showed that there are morphologic differences, and megakaryocytic morphology represents a useful clue for the differential diagnosis of these three BCR-ABL-negative MPN subtypes. Conclusion: The JAK2 V617F mutation was detected in 71% of patients with MPN disorders. Peripheral blood mutation screening for JAK2 V617F should be incorporated into the initial evaluation of patients suspected to have MPNs. Differences in megakaryocytic morphology provide the histomorphological hallmark of BCR-ABL-negative MPN subtypes.

Keywords

Janus-associated kinase 2 mutation - marrow morphology - myeloproliferative neoplasm

Full Text

References

References
1 Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14-22
2 Campbell PJ, Green AR. Myeloproliferative disorders. In: Hoffbrand AV, Catovsky D, Tuddenham EG, Green AR, editors. Postgraduate Haematology. 6th ed. London: Wiley-Blackwell A John Wiley & Sons, Ltd., Publication; 2011. p. 686.
3 Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. et al. The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications. Blood 2011; 117: 5019-32
4 Vassiliou G, Green AR. Myeloproliferative disorders (46). In: Hoffbrand AV, Catovsky D, Tuddenham D, editors. Postgraduate Haematology. 5th ed. Oxford: Blackwell Ltd.; 2006. p. 761-70.
5 Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E. et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005; 106: 3377-9
6 Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-61
7 Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-90
8 Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P. et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 2006; 107: 4139-41
9 Muhammad Arif S, Suhaib A, Nadir A. Frequency of Janus associated kinase 2 (JAK2) mutation inpatients of BCR-ABL negative myeloproliferative neoplasms. PAFMJ. 2013:63(2)
10 Boiocchi L, Mathew S, Gianelli U, Iurlo A, Radice T, Barouk-Fox S. et al. Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage. Mod Pathol 2013; 26: 1577-85
11 Sazawal S, Bajaj J, Chikkara S, Jain S, Bhargava R, Mahapatra M. et al. Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders. Indian J Med Res 2010; 132: 423-7
12 Kaifie A, Kirschner M, Wolf D, Maintz C, Hänel M, Gattermann N. et al. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): Analysis from the German SAL-MPN-registry. J Hematol Oncol 2016; 9: 18
13 Alvarez-Larrán A, Cervantes F, Bellosillo B, Giralt M, Juliá A, Hernández-Boluda JC. et al. Essential thrombocythemia in young individuals: Frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia 2007; 21: 1218-23
14 Spivak JG, Barosi G, Tognoni G, Barbui T, Finazzi G, Marchioli R. et al. Chronic myeloproliferative disorders Hematology. Am Soc Hematol Educ Program 2003; 2003: 200-24
15 Ross C, Navya Vanamala, Rameshkumar K. et al. Polycythemia vera and essential thombocythemia – A single institution experience. Clin Indian J Med Paediatr Oncol 2008; 29: 4
16 Suksomyos N, Supantitra C, Chuanchom M, Rojnuckarin P. et al. Prevalence of JAK2V617F mutation and its clinical correlation in Thais with myeloproliferative neoplasm. Int J Biol Med Res 2012; 3: 1801-5
17 Cervantes F, Tassies D, Salgado C, Rovira M, Rozman C. et al. Acute transformation in nonleukemic chronic myeloproliferative disorders: Actuarial probability and main characteristics in a series of 218 patients. Acta Haematol 2013; 2: 4-7
18 Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: A single-institution experience with 91 cases. Blood 2005; 105: 973-7
19 Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C. et al. The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): A comprehensive approach based on morphology, cytogenetics, and molecular markers. Ann Hematol 2008; 87: 1-0
20 Jan Jacques M, Fibo W, Hendrik D, Alain G. et al. Bone marrow features and natural history of BCR/ABL-positive thrombocythemia and chronic myeloid leukemia compared to BCR/ABL negative thrombocythemia in essential thrombocythemia and polycythemia vera. J Hematol Thromboembolic Dis 2015; 3: 2
21 Wilkins BS, Erber WN, Bareford D, Buck G, Wheatley K, East CL. et al. Neonatal. Neonat 2013; 2: 4-7